Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
Maria Inez Dacoregio, Isabella Michelon, Caio Ernesto do Rego Castro, Francisco Cézar Aquino de Moraes, Guilherme Rossato de Almeida, Lis Victória Ravani, Maysa Vilbert, Ricardo Costa
Abstract
BACKGROUND: Sacituzumab Govitecan (SG), a first-in-class anti-trophoblast cell surface antigen-2-directed antibody-drug conjugate (ADC), has shown clinically meaningful improvement in outcomes of patients with breast cancer (BC). However, it has also been accompanied by significant toxicity. Thus, we conducted a systematic review and meta-analysis to evaluate the safety and tolerability of SG in this patient population. METHODS: test. RESULTS: = 78 %; p = 0.012) for those on SG. Dose reductions and treatment discontinuation were reported in 22 % and 4 % of patients, respectively, and 19 deaths (2 %) were documented. Most of them were not deemed to be treated-related. CONCLUSION: This systematic review and meta-analysis provides extensive data on the safety and management of SG toxicity in BC patients across clinical trials. Concerning rates of neutropenia, nausea diarrhea, and anemia were reported. We highlight the need for protocols establishing prophylactic measures and strategies to mitigate SG-related toxicity.